We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
101
Phathom Pharmaceuticals
PHAT
$875M
$607K 0.1%
+54,650
New +$690K
CELC icon
102
Celcuity
CELC
$4.31B
$607K 0.1%
+5,314
New +$579K
VYGR icon
103
CALL
Voyager Therapeutics
VYGR
$184M
$579K 0.1%
+150,000
New +$591K
OCGN icon
104
CALL
Ocugen
OCGN
$464M
$543K 0.09%
+300,000
New +$519K
CNTB
105
Connect Biopharma Holdings
CNTB
$147M
$526K 0.09%
+200,690
New +$523K
NVO
106
Novo Nordisk
NVO
$228B
$521K 0.09%
+14,577
New +$691K
PTHS
107
Pelthos Therapeutics
PTHS
$92.8M
$520K 0.09%
24,773
-227
-0.9% -$5.38K
EOLS icon
108
CALL
Evolus
EOLS
$371M
$515K 0.09%
125,200
+6,400
+5% +$31K
QURE icon
109
uniQure
QURE
$2.71B
$510K 0.09%
31,200
-13,800
-31% -$279K
MNKD icon
110
MannKind Corp
MNKD
$1.25B
$457K 0.08%
186,603
-115,397
-38% -$515K
MAZE
111
Maze Therapeutics
MAZE
$1.5B
$448K 0.08%
+15,000
New +$662K
JANX icon
112
CALL
Janux Therapeutics
JANX
$966M
$439K 0.07%
31,600
+1,600
+5% +$21.9K
URGN icon
113
UroGen Pharma
URGN
$1.95B
$416K 0.07%
23,155
+1,345
+6% +$27K
CORT icon
114
Corcept Therapeutics
CORT
$9.63B
$403K 0.07%
10,000
-87,445
-90% -$3.27M
LPCN icon
115
Lipocine
LPCN
$18.9M
$400K 0.07%
50,000
-210,939
-81% -$1.84M
FHTX icon
116
Foghorn Therapeutics
FHTX
$298M
$382K 0.07%
79,944
+49,314
+161% +$271K
GHRS icon
117
GH Research
GHRS
$2B
$377K 0.06%
+26,836
New +$412K
OCGN icon
118
Ocugen
OCGN
$464M
$362K 0.06%
+200,000
New +$346K
PRQR icon
119
ProQR Therapeutics
PRQR
$236M
$292K 0.05%
180,083
+12,551
+7% +$20.6K
EPRX
120
Eupraxia Pharmaceuticals
EPRX
$402M
$290K 0.05%
+40,000
New +$322K
PEPG icon
121
PepGen
PEPG
$156M
$267K 0.05%
+150,925
New +$848K
TRVI icon
122
Trevi Therapeutics
TRVI
$2.46B
$258K 0.04%
21,663
-75,521
-78% -$846K
PGEN icon
123
Precigen
PGEN
$1.76B
$214K 0.04%
+55,293
New +$227K
UPB
124
Upstream Bio Inc
UPB
$393M
$194K 0.03%
21,609
+1,109
+5% +$20K
CMPS
125
Compass Pathways
CMPS
$1.68B
$176K 0.03%
+31,885
New +$214K
3 4
5
6 7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.